Stephanie Nolen
Stephanie Nolen is a global health reporter for The New York Times. She covers access to medicines and health care, and the systems and structures that determine that access globally. She has been writing about health and other development issues in the global south for 30 years, reporting from more than 80 countries, including a dozen war zones. Her work has been recognized by several prizes, including eight National Newspaper Awards in Canada, seven Amnesty International Media Awards, and the PEN Courage Award. She has an honors bachelor of journalism degree from the University of King's College and a master's degree in development studies from the London School of Economics. Nolen is committed to upholding the standards of integrity outlined in The New York Times' Ethical Journalism Handbook and rigorously cross-checks information. She does not accept gifts or payments from any organization she might cover, protects sources, and takes extra care to explain the reporting process and obtain consent from vulnerable individuals. Nolen speaks French, Spanish, Portuguese, and Arabic and can muddle along in a number of other languages. She relies on experts in various fields but verifies their information. To contact her, email is the most efficient method: stephanie.nolen@nytimes.com.
84%
The Daily's Verdict
This author has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on the author's reporting.
Bias
90%
Examples:
- The author seems to have a strong focus on the global south and issues related to access to medicines and health care.
Conflicts of Interest
90%
Examples:
- The author has no formal training in epidemiology or any of the other sciences she uses in her work, which means she has to work hard to grasp the complexities and that helps when it comes time to explain them to readers.
Contradictions
88%
Examples:
- Current manufacturing capacity limitations may result in limited access to human insulin pens in some countries including South Africa.
- Novo Nordisk opted not to renew its contract.
Deceptions
75%
Examples:
- The company did not reply to questions about which other countries are affected.
- They're shifting the focus on the more profitable line.
Recent Articles
South Africa's Diabetes Crisis: Novo Nordisk Ends Insulin Pen Supply, Forcing Patients Back to Outdated Methods
Broke On: Wednesday, 19 June 2024South Africa faces a severe insulin pen shortage due to pharmaceutical companies prioritizing weight-loss drugs over diabetes supplies. Novo Nordisk, the previous supplier, did not renew its contract and no other company has bid for the 14 million pens needed in the next three years. Patients are now forced to use vials and syringes instead, causing concern among healthcare professionals. The global trend towards more profitable weight-loss drugs leaves many diabetes patients in low-income countries with outdated insulin delivery methods. Global Health Crisis: Childhood Vaccination Disruptions Lead to Disease Outbreaks
Broke On: Friday, 24 November 2023Over 60 million children worldwide have missed their standard childhood vaccines due to disruptions in health systems during the Covid-19 pandemic. As of mid-2023, 47 countries reported serious measles outbreaks, Nigeria is facing the largest diphtheria outbreak in its history, and 12 countries are reporting circulating polio virus. The UK is experiencing a measles outbreak, with outbreaks occurring in London, Wales, and Leicester. The Union Health Ministry of India refutes the claim that half of the 22 million children who did not get their first measles shot in 2022 live in 10 countries including India, stating that only 21,000 Indian children did not get the shot.